Bullet Biotechnology Inc. is using new sequencing and manufacturing methods to develop an idiotype cancer vaccine that it anticipates will be more effective than first-generation products.

President and CEO Willie Quinn said the first wave of idiotype vaccines established proof of principle by showing that an epitope lifted from the clonal immunoglobulin region of a patient's malignant B cells can be reintroduced along with an immune stimulator and engender an immune response against the cancerous cells.